Related Experiment Video
Updated: May 10, 2026

06:47
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
Early regular egg exposure in infants with eczema: A randomized controlled trial
Debra J Palmer1, Jessica Metcalfe, Maria Makrides
1School of Paediatrics and Child Health, University of Western Australia, Perth, Australia. debbie.palmer@uwa.edu.au
The Journal of Allergy and Clinical Immunology
|July 2, 2013
Summary
Early regular oral egg exposure may reduce the risk of developing IgE-mediated egg allergy in infants with eczema. However, many infants show sensitization by 4 months, requiring caution during initial egg introduction.
Area of Science:
- Pediatric Allergy and Immunology
- Clinical Nutrition
- Immunology
Background:
- Observational studies suggest early allergen consumption may lower food allergy risk.
- Infants with moderate-to-severe eczema are at higher risk for developing food allergies.
Purpose of the Study:
- To investigate if early, regular oral egg exposure reduces IgE-mediated egg allergy in infants with eczema.
- To assess the safety and efficacy of early egg introduction in a high-risk infant population.
Main Methods:
- A double-blind, randomized controlled trial involving infants aged 4-8 months.
- Infants received daily pasteurized whole egg powder or rice powder.
- Primary outcome: IgE-mediated egg allergy at 12 months, confirmed by challenge and skin prick tests.
Main Results:
- A significant proportion of infants (31%) experienced allergic reactions to egg powder.
- Egg-specific IgE was present in 36% of infants before any known egg ingestion.
- While not statistically significant, the egg group had a lower incidence of IgE-mediated egg allergy (33% vs. 51%).
- Egg-specific IgG4 levels were significantly higher in the egg group.
Conclusions:
- Early regular oral egg exposure may induce immune tolerance and reduce egg allergy incidence in infants with eczema.
- Caution is advised due to pre-existing sensitization in many high-risk infants by 4 months of age.

